199 related articles for article (PubMed ID: 23275294)
1. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
6. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
8. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
15. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.
Chen Q; Manning CD; Millar H; McCabe FL; Ferrante C; Sharp C; Shahied-Arruda L; Doshi P; Nakada MT; Anderson GM
Clin Exp Metastasis; 2008; 25(2):139-48. PubMed ID: 18064530
[TBL] [Abstract][Full Text] [Related]
16. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
[TBL] [Abstract][Full Text] [Related]
17. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
19. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV
Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104
[TBL] [Abstract][Full Text] [Related]
20. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]